BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 925
- Registration Number
- NCT04026412
- Locations
- 🇺🇸
Local Institution - 0071, Burlington, Vermont, United States
🇺🇸Local Institution - 0124, Cleveland, Ohio, United States
🇺🇸Local Institution - 0053, Cincinnati, Ohio, United States
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Biological: NivolumabDrug: Placebo
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 461
- Registration Number
- NCT04025879
- Locations
- 🇺🇸
Local Institution - 0086, Traverse City, Michigan, United States
🇺🇸Local Institution - 0103, Fredericksburg, Virginia, United States
🇨🇦Local Institution - 0062, Oshawa, Ontario, Canada
A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT04016753
- Locations
- 🇺🇸
Altasciences Los Angeles (Formerly WCCT Global), Cypress, California, United States
An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 132
- Registration Number
- NCT04008992
- Locations
- 🇳🇱
PRA Health Sciences - Groningen, Groningen, Netherlands
🇬🇧Richmond Pharmacology, London, United Kingdom
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 881
- Registration Number
- NCT04008030
- Locations
- 🇦🇷
Local Institution - 0084, Buenos Aires, Argentina
🇦🇷Local Institution - 0100, Caba, Argentina
🇦🇷Local Institution - 0072, Caba, Argentina
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 219
- Registration Number
- NCT03994601
- Locations
- 🇺🇸
Local Institution - 0075, Costa Mesa, California, United States
🇺🇸Local Institution - 0050, Orange, California, United States
🇪🇸Local Institution - 0024, Majadahonda, Spain
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT03981094
- Locations
- 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States
A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 261
- Registration Number
- NCT03980314
- Locations
- 🇺🇸
Local Institution - 0043, Pittsburgh, Pennsylvania, United States
🇧🇷Local Institution - 0039, Barretos, Sao Paulo, Brazil
🇧🇷Local Institution - 0041, Rio de Janeiro, Brazil
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT03978611
- Locations
- 🇺🇸
Local Institution - 0002, Los Angeles, California, United States
🇧🇪Local Institution - 0018, Bruxelles, Brussels, Belgium
🇧🇪Local Institution - 0016, Brussels, Belgium
A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT03979248
- Locations
- 🇳🇱
PRA Health Sciences - Netherlands, Groningen, Netherlands